The maximum dose level in Follicum’s clinical phase I/IIa study has now been administered to the first healthy volunteer without any negative effects being seen, achieving the study’s initial dose escalating part without any problems. The clinical study was initiated on 19 January 2016. The first participant in the study was administered with the maximum […]
On 19 January 2016 the first healthy volunteer received treatment with FOL-005, initiating the clinical phase I/IIa safety/efficacy study according to Follicum’s previously communicated time plan. Previously FOL-005 has shown effective inhibition of hair growth on living human skin tissue in vitro but this is the first time it has been used in man. Treatment of around […]
Today Follicum obtained approval from the BfArM (the Federal Institute for Drugs and Medical Devices in Germany) and the research ethics committee to start a clinical Phase I/II a study. The study will now proceed according to the previously communicated plan. The study will be performed by the Clinical Research Center for Hair and Skin […]
Follicum today reported publication of its Q3 2015 interim report in Swedish. Below is a short summary of activities during the period: Significant activities during third quarter 2015: -On 1 September the company announced that the two toxicity studies which had been ongoing since March were completed, showing positive results. -In September Follicum initiated a collaboration […]
The utilization period of the TO 1 series warrants issued in conjunction with Follicum’s initial public offering ended on 17 November, warrants were converted at a rate of 99.36%. This provides additional funding of about 6.96 MSEK before issuing costs to Follicum. For more information, please contact Jan Alenfall, CEO Tel +46 (0) 46 19 […]
Tomorrow, October 27, 2015, the utilization period of the series TO 1 warrants issued in conjunction with Follicum’s initial public offering starts. The utilization period will run until November 17, 2015. Warrant holders are entitled to subscribe for one new share in Follicum for each warrant at a price of SEK 6.00 per share. For more […]
Follicum’s Interim Report for the Q3 period (1 July to 30 September 2015) will be published later than previously communicated. The original date for publication was the 25 November 2015, but the new date for publication has been changed to 30 November 2015. For more information, please contact: Jan Alenfall, CEO Tel: +46 (0)46 19 […]
Follicum has filed a clinical trial application to start a clinical Phase I / II a study to both the the BfArM (the Federal Institute for Drugs and Medical Devices in Germany) and to the Research Ethics Committee. Follicum’s intention is to initiate the study at year-end 2015/early 2016, provided that the application is accepted. […]
In March 2015 Follicum announced that the so called ”Research and Grow”- program which was financed by VINNOVA* could be finalized earlier than planned due to the promising outcome of the program. The company has now received the final results from the program, which come from the specific tissue analysis on human skin from the […]
Follicum has received a preliminary approval – a so called “Intention to Grant” – by the European Patent Office (EPO) regarding the company’s patent application for stimulation of hair growth. To read the full press release (in Swedish) please click here. For more information about Follicum’s research results, please contact: Jan Alenfall, CEO Tel +46 (0)46 19 21 […]